Literature DB >> 22236095

Outcome in dogs with surgically resected oral fibrosarcoma (1997-2008).

S A Frazier1, S M Johns, J Ortega, A L Zwingenberger, M S Kent, G M Hammond, C O Rodriguez, M A Steffey, K A Skorupski.   

Abstract

Oral fibrosarcoma (FSA) is a common oral tumour in dogs, and historically reported survival times after surgical excision range from 7.0 to 12.2 months with local recurrence rates of 32-57%. The purpose of this retrospective study was to report outcome in a cohort of dogs with oral FSA treated with surgical excision with or without adjuvant radiation therapy. Twenty-nine dogs with a histological diagnosis of FSA arising from the oral cavity that underwent surgical resection of their oral FSA were included in this study. Twenty-one dogs were treated with surgical excision alone and eight dogs with both surgery and radiation therapy. The median progression-free interval was >653 days. The median survival time was 743 days. The 1- and 2-year survival rates were 87.7 and 57.8%, respectively. Seven (24.1%) dogs developed local recurrence. Seven dogs (24.1%) developed metastasis.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 22236095     DOI: 10.1111/j.1476-5829.2011.00272.x

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  4 in total

1.  Treatment of Iron-Loaded Veterinary Sarcoma by Artemisia annua.

Authors:  Elmar Breuer; Thomas Efferth
Journal:  Nat Prod Bioprospect       Date:  2014-04-12

Review 2.  Imaging in Non-neurologic Oncologic Treatment Planning of the Head and Neck.

Authors:  Katherine S Hansen; Michael S Kent
Journal:  Front Vet Sci       Date:  2019-03-28

Review 3.  Locoregional Flap Reconstruction Following Oromaxillofacial Oncologic Surgery in Dogs and Cats: A Review and Decisional Algorithm.

Authors:  Michel Guzu; Diego Rossetti; Philippe R Hennet
Journal:  Front Vet Sci       Date:  2021-05-21

4.  Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro.

Authors:  Milan Milovancev; Stuart C Helfand; Kevin Marley; Cheri P Goodall; Christiane V Löhr; Shay Bracha
Journal:  BMC Vet Res       Date:  2016-06-04       Impact factor: 2.741

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.